Latest Intellectual Property News

1414 Degrees (ASX:14D) has partnered with European space company Orbit Boy to test its SiNTL silicon-anode battery technology for satellite and rocket applications, aiming to break into the growing space battery market.

Firebird Metals has placed all critical equipment orders for its Perth-based Australian Demonstration Plant, triggering the first ARENA grant payment and setting the stage for a pivotal 90-day fabrication phase. The project remains on track for early Q4 2026 equipment delivery, with imminent lithium manganese rich cathode results expected from its China pilot plant.

Critical Resources has achieved a key milestone by depositing a complete solid-state battery cathode layer in one dry, solvent-free step, potentially simplifying and cutting costs in battery production for high-demand sectors.

Environmental Clean Technologies (ASX: ECT) has completed a pilot Rapid Electrothermal Mineralisation system that delivers 18 times the power of its lab prototype, enabling additive-free, in-situ PFAS destruction and targeting a field demonstration in H2 2026.

Felix Gold has created Frontier Antimony Refinery Corp., a US-focused refining platform with secured access to military-grade antimony ore from its Treasure Creek Project in Alaska, aiming to address critical supply gaps.

Syntara Limited has completed a $0.84 million Share Purchase Plan, boosting its total capital raise to $8.84 million to fund multiple clinical trials and patent development through to Q3 2027.

dorsaVi has secured exclusive rights to two key robotics patents from NTU Singapore, filling critical gaps in safety control and data acquisition to expand into collaborative robotics and exoskeleton markets.

Boresight Ltd (ASX: BST) is seeking to raise $8 million through a public offer to expand its cost-effective military drone manufacturing, targeting growth in the US and European markets.

First Graphene accelerates its US expansion by acquiring MITO Material Solutions, gaining functionalised graphene technologies and a direct commercial foothold in the world’s largest defence and aerospace market.

Racura Oncology has secured $31.2 million in funding to advance its lead cancer drug RC220, including a strategic $1 million private placement to a specialist healthcare investor.

Opthea Limited resumes ASX trading as it pivots to develop OPT-302 for lymphangioleiomyomatosis, outlining a disciplined 18-month staged clinical program backed by A$31.2 million in cash.

Biome Australia has inked a binding deal with Specialty Probiotics Australia to shift its Activated Probiotics manufacturing onshore, aiming to boost gross margins above 65% and streamline working capital within 18 months.